Shares of Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $15.00.
Several equities analysts recently issued reports on WVE shares. HC Wainwright boosted their target price on shares of Wave Life Sciences from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Royal Bank of Canada increased their target price on shares of Wave Life Sciences from $5.00 to $7.00 and gave the stock a “sector perform” rating in a research note on Friday, October 4th. JPMorgan Chase & Co. began coverage on Wave Life Sciences in a research note on Friday, September 27th. They issued an “overweight” rating and a $13.00 price target for the company. B. Riley increased their price target on Wave Life Sciences from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Finally, Mizuho restated an “outperform” rating and issued a $19.00 price objective on shares of Wave Life Sciences in a research report on Tuesday, June 25th.
Check Out Our Latest Research Report on WVE
Insider Transactions at Wave Life Sciences
Institutional Trading of Wave Life Sciences
Several large investors have recently added to or reduced their stakes in the stock. Emerald Advisers LLC purchased a new stake in shares of Wave Life Sciences in the 2nd quarter valued at approximately $12,441,000. Emerald Mutual Fund Advisers Trust acquired a new position in Wave Life Sciences in the second quarter valued at approximately $9,086,000. Artal Group S.A. grew its position in Wave Life Sciences by 34.7% in the first quarter. Artal Group S.A. now owns 4,051,400 shares of the company’s stock worth $24,997,000 after acquiring an additional 1,044,000 shares during the period. Ikarian Capital LLC acquired a new stake in Wave Life Sciences during the first quarter worth $3,641,000. Finally, Vanguard Group Inc. raised its position in Wave Life Sciences by 39.7% in the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock valued at $11,316,000 after purchasing an additional 521,665 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.
Wave Life Sciences Stock Performance
Shares of WVE opened at $8.00 on Friday. The business’s 50-day moving average is $6.30 and its two-hundred day moving average is $5.95. The company has a market capitalization of $979.80 million, a P/E ratio of -15.38 and a beta of -1.10. Wave Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $9.92.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. During the same period last year, the business earned ($0.20) earnings per share. Analysts forecast that Wave Life Sciences will post -1.02 EPS for the current year.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Recommended Stories
- Five stocks we like better than Wave Life Sciences
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.